托珠单抗与肿瘤坏死因子抑制剂在类风湿关节炎患者中的心血管安全性比较:多数据库队列研究
该多数据库队列研究比较了类风湿关节炎患者启用托珠单抗(TCZ)与肿瘤坏死因子抑制剂(TNFi)的心血管风险。研究纳入9,218例TCZ启用者与18,810例TNFi启用者,复合心血管事件发生率分别为0.52/100人年与0.59/100人年,合并HR为0.84(95%CI 0.56-1.26),未发现TCZ增加心血管风险。
要点
- TCZ与TNFi的心血管复合终点风险相似,合并HR 0.84(95%CI 0.56-1.26)。
- TCZ组心血管事件发生率为0.52/100人年,TNFi组为0.59/100人年。
- 研究人群为既往使用过其他TNFi、阿巴西普或托法替布后换药的RA患者。
核心结论
- 在换用生物制剂或托法替布的RA患者中,启用TCZ相比TNFi未观察到心血管风险增加。
研究设计与样本
- 基于Medicare、IMS PharMetrics和MarketScan理赔数据的多数据库队列研究。
- 纳入新启用TCZ或TNFi且既往使用过其他TNFi、阿巴西普或托法替布的RA患者。
- TCZ启用者按可变比例1:3倾向性评分匹配至TNFi启用者,控制>65项基线特征。
- 采用固定效应模型合并各数据库的特异性风险比(HR)。
主要发现
- 共纳入9,218例TCZ启用者与18,810例TNFi启用者。
- 平均年龄:Medicare数据库72岁,PharMetrics数据库51岁,MarketScan数据库53岁。
- 基线心血管疾病患病率:TCZ组14.3%,TNFi组13.5%。
- 研究期间(平均±SD 0.9±0.7年,最长4.5年)共发生125例复合心血管事件。
- 复合心血管事件发生率:TCZ组0.52/100人年,TNFi组0.59/100人年;合并HR 0.84(95%CI 0.56-1.26)。
关键数值与推荐
- 主要结局为因心肌梗死或卒中住院的复合心血管终点。
临床怎么用
- 对于既往使用过其他生物制剂或托法替布的RA患者,换用TCZ时无需因心血管风险顾虑而优先选择TNFi。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: While tocilizumab (TCZ) is known to increase low-density lipoprotein (LDL) cholesterol levels, it is unclear whether TCZ increases cardiovascular risk in patients with rheumatoid arthritis (RA). This study was undertaken to compare the cardiovascular risk associated with receiving TCZ versus tumor necrosis factor inhibitors (TNFi). METHODS: To examine comparative cardiovascular safety, we conducted a cohort study of RA patients who newly started TCZ or TNFi using claims data from Medicare, IMS PharMetrics, and MarketScan. All patients were required to have previously used a different TNFi, abatacept, or tofacitinib. The primary outcome measure was a composite cardiovascular end point of hospitalization for myocardial infarction or stroke. TCZ initiators were propensity score matched to TNFi initiators with a variable ratio of 1:3 within each database, controlling for >65 baseline characteristics. A fixed-effects model combined database-specific hazard ratios (HRs). RESULTS: We included 9,218 TCZ initiators propensity score matched to 18,810 TNFi initiators across all 3 databases. The mean age was 72 years in Medicare, 51 in PharMetrics, and 53 in MarketScan. Cardiovascular disease was present at baseline in 14.3% of TCZ initiators and 13.5% of TNFi initiators. During the study period (mean ± SD 0.9 ± 0.7 years; maximum 4.5 years), 125 composite cardiovascular events occurred, resulting in an incidence rate of 0.52 per 100 person-years for TCZ initiators and 0.59 per 100 person-years for TNFi initiators. The risk of cardiovascular events associated with TCZ use versus TNFi use was similar across all 3 databases, with a combined HR of 0.84 (95% confidence interval 0.56-1.26). CONCLUSION: This multi-database population-based cohort study showed no evidence of an increased cardiovascular risk among RA patients who switched from a different biologic drug or tofacitinib to TCZ versus to a TNFi.
引用
- Kim SC, Solomon DH, Rogers JR, et al. Cardiovascular Safety of Tocilizumab Versus Tumor Necrosis Factor Inhibitors in Patients With Rheumatoid Arthritis: A Multi-Database Cohort Study. Arthritis Rheumatol. 2017. PMID: 28245350. doi:10.1002/art.40084
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。